Deprecated function: Creation of dynamic property MergeQuery::$condition is deprecated in MergeQuery->__construct() (line 1357 of /home/topnewse/public_html/topnewsnl/includes/database/query.inc).
Deprecated function: Creation of dynamic property DatabaseCondition::$stringVersion is deprecated in DatabaseCondition->compile() (line 1887 of /home/topnewse/public_html/topnewsnl/includes/database/query.inc).
Deprecated function: Creation of dynamic property DatabaseCondition::$stringVersion is deprecated in DatabaseCondition->compile() (line 1887 of /home/topnewse/public_html/topnewsnl/includes/database/query.inc).
Deprecated function: Creation of dynamic property DatabaseCondition::$stringVersion is deprecated in DatabaseCondition->compile() (line 1887 of /home/topnewse/public_html/topnewsnl/includes/database/query.inc).
Deprecated function: Creation of dynamic property DatabaseCondition::$stringVersion is deprecated in DatabaseCondition->compile() (line 1887 of /home/topnewse/public_html/topnewsnl/includes/database/query.inc).
As per views of Technical Analysts, Ranbaxy Labs is looking very fairly valued at current market price. The stock ended at 433.10 levels on Friday, down by Rs 9.20 or 2.08%.
Paris: Sanofi-Aventis, French pharmaceutical group has annunciated that the U.S. health officials have approved another application of its anti-cancer drug ‘Taxotere.’
The company said that the drug has been sanctioned to treat locally advanced head and neck cancer before chemo-radiotherapy and surgical treatment.
The approval is based on the outcomes of a phase III clinical examination, which showed that adding up Taxotere to typical induction chemotherapy resulted in a more than three year betterment in patient endurance rate.